HC Wainwright Lowers Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright dropped their Q2 2026 EPS estimates for TG Therapeutics in a research report issued on Tuesday, March 3rd. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings per share of $0.27 for the quarter, down from their previous forecast of $0.28. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q3 2026 earnings at $0.31 EPS, FY2026 earnings at $1.21 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.37 EPS, FY2029 earnings at $2.97 EPS and FY2030 earnings at $3.91 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). The company had revenue of $192.57 million during the quarter, compared to analysts’ expectations of $192.15 million. TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The company’s quarterly revenue was up 78.0% on a year-over-year basis. During the same period last year, the business posted $0.15 earnings per share.

A number of other research firms also recently commented on TGTX. Wall Street Zen downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. dropped their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

TG Therapeutics Stock Performance

TGTX opened at $29.03 on Thursday. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $46.48. The stock has a market cap of $4.64 billion, a P/E ratio of 10.48 and a beta of 1.87. The stock’s 50 day simple moving average is $29.70 and its 200 day simple moving average is $31.46. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 2.89.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds have recently modified their holdings of the company. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics in the second quarter valued at approximately $25,000. Danske Bank A S purchased a new stake in TG Therapeutics in the 3rd quarter worth approximately $25,000. Optiver Holding B.V. raised its holdings in TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 732 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the period. Finally, Salomon & Ludwin LLC purchased a new position in shares of TG Therapeutics during the 3rd quarter worth $34,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Company raised FY‑2026 revenue guidance to $875.0M–$900.0M, well above the consensus (~$784.9M), signaling stronger-than-expected sales that could support valuation if delivery and margins hold. Article
• Neutral Sentiment: TG updated FY‑2026 guidance but the EPS line in the release appears blank/uncertain; investors should watch for a clarified EPS target or management commentary that could swing sentiment. Article
• Negative Sentiment: HC Wainwright cut near‑term and multi‑year EPS forecasts: Q2‑2026 to $0.27 (from $0.28), Q3‑2026 to $0.31 (from $0.34), FY‑2026 to $1.21 (from $1.30) and trimmed FY‑2027–FY‑2030 estimates — these downward revisions lower growth/profit expectations and likely pressure the share multiple. Article
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss (reported $0.14 vs. $0.35 est.) despite strong revenue growth (+78% YoY); lingering concerns about profitability consistency may keep analysts cautious. Article

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.